The U.S. Hemp Roundtable, the hemp industry’s national business advocacy organization, is opposed to marketing products, under the guise of the hemp name, for any intoxicating value or euphoric effect — an irresponsible practice highlighted in recent news reports. Unlike marijuana, hemp is, by definition, not intoxicating. Rather, hemp products like CBD are popularly used by consumers to benefit their general health and wellness, not to get them high. Adult-use cannabis products, which feature concentrated THC and are intended for intoxication, should not be marketed as dietary supplements, and should be subject to a distinct regulatory pathway. We look forward to working with Congress and federal agencies to develop responsible laws and regulations to provide separate pathways and proper guardrails to distinguish these products. HR 841, which would establish a regulatory pathway for the sale of hemp-derived extracts like CBD, is an important starting point. This bill will help stabilize hemp markets, open a promising economic opportunity for U.S. farmers, and protect consumers by requiring hemp extract product manufacturers to comply with the entire existing comprehensive regulatory framework for dietary supplements.